Free Newsletter
Proteins targeted in hunt for universal flu jab
Scientists at Oxford University are testing a new universal flu vaccine that targets the internal proteins of the virus, which change very little from one strain to the next. The Phase I trial involves 12 volunteers.
"The current approach to influenza vaccination is unsatisfactory for use against seasonal influenza and of little use when new types of flu begin to infect humans from birds," said Dr. Susan Gilbert of the Jenner Institute at the University of Oxford, which is leading the research. "It leaves manufacturers with just a few months to produce the necessary stocks, the vaccine then has to be administered to at-risk populations within a short time window, and those receiving the injection will have to be vaccinated again every year. By targeting the internal proteins of the virus, we can come up with a universal flu jab. The same vaccine would work against all seasonal flu and protect against bird flu."
- read the story in Medical Laboratory World
Related Articles:
Universal flu vax works in early-stage trial
Universal flu vaccine shows early promise
Dynavax inks universal vaccine pact with Novartis
VaxInnate in a race to produce 'universal' flu vaccine (Nov 2007)
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




